Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Did Changing Sentiment Drive Advaxis's (NASDAQ:ADXS) Share Price Down A Disastrous 99%?….
https://finance.yahoo.com/news/did-changing-sentiment-drive-advaxiss-100446329.html?guccounter=1&guce_referrer=aHR0cHM6Ly9zdG9ja3R3aXRzLmNvbS9zeW1ib2wvQURYUw&guce_referrer_sig=AQAAABbQhA5xZZtqoWPeCW8wxikGpZuxRLMeCCViKKo0uWQ79ta-2qpKuE88QRhEW0X3ptfhBP9MaeL_C8iq3mc8o1AsPCnpEAS5hRdqHvUWiiXS6H0SxHw8NiUKuNS1PruPVFHZVv4DppK2rS0LHX09sMkw7KR-gowBhnv0bpu0_UQX
excellent reporting.
I found this important and complete information on the situation …
https://www.bloomberg.com/news/articles/2019-12-12/destination-maternity-to-liquidate-in-deal-u-s-called-tainted
have you already bought the title?
thanks.
I am happy and peaceful for CENTSABILITY4ME.
he has been following TSOI for many years. deserves all possible stock growth ...
too little for news releases.
it should already be at 0.005-0.006 with cap. 6 mln ...
there is something that does NOT WORK in this management, or they hide something negative from the market.
always good news in the last days.
pity that the market NEVER rewards the share price ....
always pump-dump.
next week we are going to test 0.001-0.0011...
and maybe it won't be enough !!!
no doubt.
penny stocks may have monstrous rises ...
I am also in ADXS nasdaq. maybe something is changing in ADVAXIS
I hope you're right ...
however I respect you very much SUBSLOVER.
you look too optimistic ...
with yesterday's news, it had to quote at least above 0.005-0.006.
despite the extremely low market capitalization, it does not start as it should ...
pump and dump the usual shit ....
Global Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Market Insights 2019 – Abion Inc, Advaxis Inc, Bioleaders Corp, BioNTech AG, Cancer Research Technology Ltd.
https://www.foxnews18.com/5599/global-inhibitor-of-nuclear-factor-kappa-b-kinase-subunit-beta-market-insights-2019-abion-inc-advaxis-inc-bioleaders-corp-biontech-ag-cancer-research-technology-ltd/?utm_source=dlvr.it&utm_medium=twitter
ADXS: a 2M share bet by the GREATEST HEDGE FUND the world has ever known....Renassiance Technologies
15M in volume yesterday ? Imagine if we pop over 50M....
in the medium-term chart, gap up at $6...
0,71 with 2.600.000 volumes...
closing gap at 0.90.
but will continue to rise ...
Cancer Immunotherapy Market 2019 Global Industry Size, Analysis, Growth Factors, Top Key Players and Forecast till 2026.
The Global Cancer Immunotherapy Market is increase in incidence & prevalence of cancer, technological advancements in treatment therapies the are factors augmenting the cancer immunotherapy market globally. However, side effects associated with the therapies is one of the major factors impeding the growth of the market.
The key players profiled in the market include F. Hoffmann-La Roche AG, Advaxis Inc., Merck & Co., Inc., Eli Lilly and Company Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Bayer AG, mmunomedics Inc., Astrazeneca plc…
https://vaporblash.com/2019/12/04/cancer-immunotherapy-market-2019-global-industry-size-analysis-growth-factors-top-key-players-and-forecast-till-2026/
Advaxis to Present at 12th Annual LD Micro Main Event Investor Conference.
https://stocknewsnow.com/companynews/6286161513790586/ADXS/101843
you have the 2020 deal ...
target 2.50-3.00 ...
This is one of the news items we are waiting for: PSA trial with Merck.
https://clinicaltrials.gov/ct2/show/NCT02325557?term=NCT02325557&draw=2&rank=1
with the right news, even $ 2.5 or 3$ ...
the company is worth 1.73 $ m for the market.
the market never lies ...
strong volumes, but above all in the right direction ... + 22%.
generally almost all bounces, start after a minimum on the weekly and bollinger bands.
no, I can't post.
however, make sure that this is the case, if you open a weekly chart the minimum base of the bollinger bands is 0.0004-0.0005.
the minimum before a rebound, will be in area 0.0004-0.0005 which corresponds to the lower base of the bollinger bands on the weekly chart ...
every day part negative and with difficulty.
but later in the day he always recovers well ... and with strong volumes ...
in your opinion, when could they give you the first important data?
thanks.
TSOI managers are not interested in shareholders !!!
in January 2019 we were at 0.004 ...
Today's TSOI movement is embarrassing and even irritating.
after an important agreement, it is incredibly bearish ...
we will never return to the area of ??0.004-0.005.
but what must happen to make this title take off?
must buy WARREN BUFFETT ????
new absolute minimum coming ...
0.0008 to 0.0009
TSOI = CLOWN COMPANY !!!
TIM spoke of growth for shareholders in 2019 ...
CENTS. don't change the cards on the table !!!
they are liars and thieves !!!
the letter to the shareholders of Tim G Dixon, for the moment has had no stock growth for TSOI shareholders…..
TIM you are a liar !!!
finally the volumes return.
ten million pieces traded ..
a few more days, some important news will come out.
ADXS-HPV: Axalimogene filolisbac (AXAL):
– Cervical Cancer – As announced in July, the company is in the process of winding down its Phase 3 AIM2CERV study evaluating AXAL for the treatment of patients with high-risk, locally advanced cervical cancer. As a result of the closure of this study, the company will be unblinding the data and anticipates reporting the results of the 110 patients that had been dosed with AXAL in this study by the end of 2019.
– Lung Cancer –Global BioPharma, Inc. (GBP), the company’s partner in certain Asian and African territories, anticipates initiating its Phase 2, open-label controlled trial in HPV-associated NSCLC in patients following first-line chemotherapy by the end of 2019. The study will be assessing the effects of AXAL when combined with pemetrexed in patients with HPV+ NSCLC, following first line induction therapy.
“At Advaxis, we are committed to unlocking the potential benefits of our Lm TechnologyTM platform to improve outcomes for cancer patients,” said Kenneth A. Berlin, President and Chief Executive Officer of Advaxis. “The NEO trial has provided us with valuable proof-of-mechanism data for our HOT program, with clinical signals of generation of CD8+ T cells against hotspot mutations, antigen spreading and stable disease in two patients. While discontinuing the NEO program was a difficult decision, we ultimately believe that the off-the-shelf approach of our HOT program will allow us to more effectively evaluate our platform in a broad patient population with a more economical, commercial-ready manufacturing process while also extending our cash runway until early 2021. I want to personally thank the patients, employees and collaborating physicians who participated in or assisted with this study.” He concluded, “The strength of our technology and pipeline leave us well positioned to explore a variety of strategic opportunities heading into 2020.”
October 26, 2019 Stocks News Feed
PRINCETON, N.J.–(BUSINESS WIRE)–Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the following updates to its clinical programs.
https://stocksnewsfeed.com/businesswire/advaxis-announces-business-and-pipeline-update/?utm_source=dlvr.it&utm_medium=twitter
only two months are left until the end of 2019.
we are far below the listing at the beginning of the year. the letter to the shareholders of Tim G Dixon, for the moment has had no stock growth for TSOI shareholders.
TSOI ALARM, you have to do a lot more TIM ...
we want more value for shareholders, we want commercial agreements with big companies, we want profits in TSOI's balance sheet.
THE LETTER TO THE SHAREHOLDERS OF Dec. 31, 2018 IS A FAILURE ???
maybe closing the gap at 0.85 ...
usually before a strong rise, they make one two rounds of sharp declines with large volumes ...